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Abstract: The aim of this study was to investigate retinal and choriocapillaris vessel changes in
diabetic macular edema (DME) after the intravitreal dexamethasone implant (IDI) using optical
coherence tomography angiography (OCTA). Moreover, a comparison between morphological and
functional parameters of DME and healthy patients was performed. Twenty-five eyes of 25 type 2
diabetic retinopathy patients complicated by macular edema (DME group) and 25 healthy subjects
(control group) were enrolled. Superficial capillary plexus density (SCPD) and deep capillary plexus
density (DCPD) in the foveal and parafoveal areas, choricapillary density (CCD) and optic disc vessel
density (ODVD) were detected using OCTA at baseline and after 7, 30, 60, 90 and 120 days post
injection. Best corrected visual acuity (BCVA), retinal sensitivity, and central retinal thickness (CMT)
were also evaluated in both groups of patients. A statistically significant difference between the two
groups (DME and controls) was found in terms of functional (MP, p < 0.001 and BCVA, p < 0.001)
and morphological (CMT, p < 0.001; SCPD in the parafoveal area, p < 0.001; DCPD in the foveal area,
p < 0.05 and parafoveal area, p < 0.001; CCD, p < 0.001) parameters. After the treatment, SCPD and
DCPD in the foveal and parafoveal areas did not modify significantly during the follow up.
Keywords: optical coherence tomography angiography; diabetic macular edema; intravitreal
dexamethasone implant; diabetic retinopathy
1. Introduction
Diabetic retinopathy (DR) is one of the leading causes of vision loss and blindness in the working
age population [1].
Regardless of the widespread use of new therapies, including the anti-vascular endothelial
growth factor (VEGF) agents and corticosteroids, diabetic macular edema (DME) remains a common
DR complication, and it is estimated to affect about 20% of the diabetic retinopathy patients in the
United States [2].
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The DME etiology is still being investigated, and it is probably related to an inflammatory
condition [3].
Capillary leakage and fluid accumulation, due to a breakdown of the blood-retinal barrier, involve
the expression of inflammatory factors, such as intercellular adhesion molecule-1, interleukin-6,
monocyte chemotactic protein-1, leukostasis and VEGF [3].
In the armamentarium of intravitreal agents, the anti VEGFs were the first drugs approved for
diabetic macular edema treatment [4].
Nevertheless, the intravitreal dexamethasone implant (IDI) is considered an effective
corticosteroid in the treatment of DME. It has been demonstrated that IDI is six times more effective
than intravitreal triamcinolone acetonide [5,6].
Together with the development of modern drugs for DME treatment, new imaging techniques are
now part of the routine follow up of the diabetic retinopathy (DR) patients.
Nowadays, the introduction of optical coherence tomography angiography (OCTA) allows for
the precise and detailed visualization of retinal and choroidal blood vessels without using injectable
dyes, and it has been used for the diagnosis and follow up of several vascular retinal diseases [7,8].
Although Fluorescein angiography (FA) is still the gold standard for the diagnosis and the
evaluation of retinal microvascular alterations, it has some limitations in the optimal visualization of
deep retinal vessels [9].
The aim of this prospective study was to evaluate morphological macular and peripapillary
retinal vascular changes in patients with DR complicated by DME before and after IDI using XR
Avanti® AngioVue OCTA (Optovue Inc., Fremont, CA, USA) based on the split spectrum amplitude
decorrelation angiography (SSADA) algorithm, and to compare them with functional parameters.
In addition, a comparison between morphological and functional parameters of DME patients and
healthy subjects was performed.
2. Results
2.1. Demographic Data
A total of 50 patients were enrolled in this study from June 2016 throughout January 2017.
Twenty-five eyes of 25 type 2 diabetic patients (DME group) (13 males; 12 females; mean age of
62.3 ± 8.3 years) with DME treated with IDI were evaluated for the analysis.
All diabetic subjects were treatment naïve patients.
A control group of 25 healthy patients (control group) (11 males; 14 females; mean age of
61.8 ± 6.8 years) was also enrolled.
No treatment-related complications were observed during the follow up, including intraocular
pressure increase requiring hypotonic eye drops and progression of lens opacity evaluated by means
of Lens Opacities Classification Systems (LOCS III) [10,11].
2.2. Functional Parameters at Baseline
The mean Best corrected visual acuity (BCVA) and 4◦ microperimetry (MP) values are reported in
Table 1.
A statistically significant difference was found between the two groups of patients in terms of
functional parameters (MP and BCVA).
The mean BCVA at the baseline was 0.6 ± 0.1 logMAR in the DME group and 0.1 ± 0.1 logMAR
in the control group (p < 0.001) (Table 1).
The mean microperimetry sensitivity at the baseline was 4.9 ± 4.3 dB in the DME group and
15.0 ± 1.4 dB in the control group (p < 0.001) (Table 1).
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Table 1. Mean and standard deviation of morphological parameters (central macular thickness and
vessel density of superficial capillary plexus, deep capillary plexus and choriocapillaris) and functional
parameters (microperimerty and best corrected visual acuity).
Variable Control DME p-Value a
CMT (µm)
Fovea 252.7 ± 20.0 462.1 ± 109.6 <0.001
Parafovea 314.0 ± 13.9 441.3 ± 80.5 <0.001
SCPD (µm)
Whole 50.2 ± 3.6 40.7 ± 4.5 <0.001
Fovea 32.8 ± 7.8 29.6 ± 5.4 0.263
Parafovea 51.7 ± 4.3 41.3 ± 4.8 <0.001
Parasuperior 52.1 ± 5.2 39.5 ± 6.7 <0.001
Parainferior 51.3 ± 4.0 41.4 ± 6.6 <0.001
DCPD (µm)
Whole 58.5 ± 3.4 45.1 ± 5.2 <0.001
Fovea 28.5 ± 8.3 18.9 ± 9.2 0.016
Parafovea 61.1 ± 4.3 47.9 ± 5.1 <0.001
Parasuperior 61.1 ± 5.6 45.3 ± 7.5 <0.001
Parainferior 61.1 ± 3.7 47.4 ± 5.8 <0.001
CCD (µm)
Whole 66.7 ± 1.1 63.5 ± 2.2 <0.001
Fovea 66.0 ± 4.1 60.7 ± 5.8 0.016
Parafovea 65.7 ± 1.7 63.5 ± 2.1 0.010
Parasuperior 65.5 ± 2.2 63.7 ± 2.4 0.042
Parainferior 65.9 ± 1.6 63.3 ± 2.4 0.004
ODVD (µm)
Whole 54.6 ± 3.6 51.7 ± 4.4 0.164
Inside 42.2 ± 10.6 46.0 ± 10.1 0.431
Peripapillary 61.5 ± 3.7 57.5 ± 4.7 0.021
4◦ MP (dB) 15.0 ± 1.4 4.9 ± 4.3 <0.001
BCVA (logMAR) 0.1 ± 0.1 0.6 ± 0.1 <0.001
a Student t-test DME vs. control. Bolded p-value are significant after FDR correction. FDR = false discovery rate;
CMT = Central Macular Thickness; SCPD = Superficial capillary plexus density; DCPD = Deep capillary plexus
density; CCD = Choriocapillaris density; ODVD = Optic disc vessel density; MP = microperimetry; BCVA = best
corrected visual acuity.
2.3. Morphological Parameters at Baseline
A statistically significant difference was found between the DME group and control group in
terms of morphological parameters (Table 1).
The mean central macular thickness (CMT) in the foveal area at the first visit was 462.1± 109.6 µm
in DME group and 252.7 ± 20.0 µm in the control group (p < 0.001) (Table 1).
The mean superficial capillary plexus (SCPD), the mean deep capillary plexus density (DCPD),
the mean choriocapillaris density (CCD), and the mean optic disk vessel density (ODVD) are described
in Table 1.
Overall, retinal vessel density was significantly reduced in DME patients in comparison with
controls (Table 1).
Superficial retinal vessels in the macular area were diffusely rarified with disruption of perifoveal
anastomotic arcades. In the deep retinal plexus, a rarefaction of vessel density was observed with
telengectatic appearance of retinal vessels particularly in the areas of macular edema.
Vessels of the optic disc were not statistically different between the two groups (p = 0.431) (Table 1),
while peripapillary vessel density was significantly reduced in the DME group compared to the control
group (p = 0.021).
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Chorocapillaris density at baseline was significantly reduced in DME group in comparison with
control group, both in the foveal and parafoveal areas (Table 1).
2.4. Post Treatment Qualitative and Quantitative Analysis
CMT in the foveal area significantly decreased at the postoperative controls from 462.1± 109.6 µm
to 305.8 ± 53.9 µm at 30 days and 286.7 ± 53.9 µm at 60 days. After 90 days from the implant CMT
started to increase to 307.8 ± 60.1 µm and reached 426.0 ± 95.7 µm 120 days after the treatment
(Table 2).
Table 2. Mean and standard deviation of morphological and functional parameters at baseline and
after intravitreal dexamethasone implant.
Variable Baseline 7 Days 30 Days 60 Days 90 Days 120 Days p-Value a
CMT (µm)
Fovea 462.1 ± 109.6 347.1 ± 54.7 305.8 ± 53.9 * 286.7 ± 53.9 ** 307.8 ± 60.1 * 426.0 ± 95.7 0.001
Parafovea 441.3 ± 80.5 375.3 ± 33.0 349.7 ± 27.3 ** 344.9 ± 25.4 * 356.5 ± 31.2 403.7 ± 37.3 * <0.001
SCPD (µm)
Whole 40.7 ± 4.5 39.9 ± 4.2 * 41.4 ± 4.9 41.7 ± 4.8 40.6 ± 3.1 41.3 ± 3.6 0.928
Fovea 29.6 ± 5.4 26.7 ± 6.6 26.1 ± 9.4 23.7 ± 9.5 * 27.9 ± 15.1 28.3 ± 3.2 0.311
Parafovea 41.3 ± 4.8 40.2 ± 4.9 41.9 ± 5.5 42.4 ± 5.7 41.0 ± 3.9 41.5 ± 3.9 0.875
Parasuperior 39.5 ± 6.7 39.6 ± 5.6 42.8 ± 6.1 40.0 ± 5.3 41.3 ± 3.5 42.3 ± 3.0 0.491
Parainferior 41.4 ± 6.6 40.9 ± 5.1 43.1 ± 4.8 40.9 ± 4.5 * 41.5 ± 5.4 41.8 ± 4.4 0.296
DCPD (µm)
Whole 45.1 ± 5.2 46.4 ± 5.0 48.3 ± 4.3 46.9 ± 4.3 42.8 ± 6.9 47.2 ± 6.3 0.210
Fovea 18.9 ± 9.2 23.3 ± 12.0 26.7 ± 10.0 24.5 ± 6.8 26.7 ± 6.9 20.9 ± 8.7 0.205
Parafovea 47.9 ± 5.1 48.2 ± 5.3 50.6 ± 5.1 48.7 ± 5.2 44.5 ± 6.4 49.1 ± 7.4 0.144
Parasuperior 45.3 ± 7.5 48.4 ± 5.4 50.9 ± 4.9 49.6 ± 5.2 * 45.4 ± 5.9 50.8 ± 4.9 0.110
Parainferior 47.4 ± 5.8 48.1 ± 5.7 50.2 ± 5.4 47.7 ± 5.5 43.7 ± 7.0 47.5 ± 10.1 0.269
CCD (µm)
Whole 63.5 ± 2.2 63.9 ± 1.5 64.8 ± 1.8 65.4 ± 1.6 64.6 ± 1.7 61.6 ± 6.3 0.414
Fovea 60.7 ± 5.8 61.4 ± 6.1 65.8 ± 2.9 64.7 ± 5.8 63.9 ± 5.6 60.9 ± 8.5 0.188
Parafovea 63.5 ± 2.1 64.0 ± 1.4 64.5 ± 2.0 65.3 ± 1.5 64.1 ± 1.4 60.8 ± 6.8 0.353
Parasuperior 63.7 ± 2.4 64.2 ± 1.5 64.5 ± 2.1 * 65.9 ± 1.7 63.9 ± 1.5 60.6 ± 7.3 0.261
Parainferior 63.3 ± 2.4 63.8 ± 1.9 64.4 ± 2.2 64.6 ± 1.7 64.3 ± 1.8 61.0 ± 6.4 0.497
ODVD (µm)
Whole 51.7 ± 4.4 51.0 ± 3.1 50.2 ± 4.5 50.2 ± 2.9 50.4 ± 3.6 49.2 ± 3.8 0.573
Inside 46.0 ± 10.1 45.8 ± 10.5 42.9 ± 9.7 45.0 ± 8.8 42.8 ± 10.2 42.7 ± 10.4 0.452
Peripapillary 57.5 ± 4.3 56.5 ± 4.4 55.2 ± 5.8 55.5 ± 3.7 56.4 ± 4.7 54.5 ± 5.8 0.363
4◦ MP (dB) 4,9 ± 4,3 6.5 ± 4.6 ** 7.5 ± 4.7 ** 7.4 ± 5.1 7.1 ± 5.4 5.5 ± 5.6 0.611
BCVA (logMAR) 0.6 ± 0 0.5 ± 0.5 0.4 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.001
a Repeated-measures ANOVA with linear trend analysis. Bolded p-value are significant after FDR correction.
* p < 0.05; ** p < 0.01 contrast analysis vs. previous measure. FDR = false discovery rate; CMT = Central
Macular Thickness; SCPD = Superficial capillary plexus density; DCPD = Deep capillary plexus density;
CCD = Choriocapillaris density; ODVD = Optic disc vessel density; MP = microperimetry; BCVA = best corrected
visual acuity.
Overall, SCPD, DCPD and CCD did not modify significantly during the follow up.
Nevertheless, CCD showed a weak increasing trend from 60.7 ± 5.8 to 64.7 ± 5.8 at 60 days in the
foveal region.
At qualitative analysis, after partial or complete resolution of macular edema, superficial and deep
retinal vessels were still rarefied, but in the deep plexus vessels appeared less telangectatic (Figure 1).
During the entire follow up period, the ODVD did not show any statically significant difference
(Table 2).
The retinal sensitivity at microperimetry significantly improved at 7, 30, and 60 days after the IDI
with stable values up to 90 days and a slight not significant decrease at 120 days.
BCVA showed a tendency to an increase with the highest value at 60 days remaining stable
thereafter (0.3 ± 0.2 logMAR).
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Figure 1. Spectral optical coherence tomography (SDOCT) and OCT angiography (OCTA) images of 
a patient with diabetic macular edema before and 60 days after intravitreal dexamethasone implant 
(IDI). SDOCT horizontal scan at baseline ((a): top) showing intraretinal cystoid macular edema and 
subretinal fluid that almost completely resolved after IDI implant ((a): bottom). OCTA of superficial 
plexus ((b): top) showing reduction of superficial vessel density and interruption of perifoveal 
anastomotic arcades with partial increase of vessel density after edema disappearance at 60 days after 
IDI implant ((b): bottom). OCTA of the deep plexus at baseline ((c): top) showing telangiectatic and 
rarified vessels and no flow areas related to retinal cysts and hard exudates; after IDI implant ((c): 
top) it is evident a reduction of vessel caliber appearing less angiectatic, a vessel density increase and 
partial cysts disappearance. OCTA of choriocapillaris ((d): top) at baseline showing focal areas of no 
flow probably related to a masking effect due to retinal edema and hard exudate that partially 
decrease after IDI ((d): bottom). 
2.5. Correlation Analysis between Different Parameters 
SCPD and DCPD relative variation from baseline to 120 days in the foveal and parafoveal area 
did not show any significant correlation with foveal and parafoveal CMT relative variation (Table 3). 
Table 3. Pearson’s Correlation coefficient among thickness, density, and functional parameters expressed 
as relative variation from baseline to 120 days. 
Variable CMT Fovea CMT Parafovea
SCPD   
Whole −0.490 −0.121 
Fovea −0.322 0.224 
Parafovea −0.470 0.034 
DCPD   
Whole 0.187 0.616 
Fovea −0.220 0.132 
Parafovea 0.308 0.689 
CCD   
Whole −0.146 0.048 
Fovea −0.724 ** −0.799 ** 
Parafovea −0.222 0.078 
ODVD   
Whole −0.243 −0.131 
Inside −0.044 0.220 
Peripapillary −0.543 −0.257 
4° MP −0.028 0.251 
BCVA 0.123 −0.365 
* p < 0.05; ** p < 0.01 after FDR correction. FDR = false discovery rate, CMT = Central Macular 
Thickness; SCPD = Superficial capillary plexus density; DCPD = Deep capillary plexus density; CCD 
= Choriocapillaris density; ODVD = Optic disc vessel density; MP = microperimetry; BCVA = best 
corrected visual acuity. 
Figure 1. Spectral optical coherence tomogra ) d CT angiography (OCTA) images of
a patient with diabetic macular edema before a i travitreal dexamethasone implant
(IDI). SDOCT horizontal scan at baseline ((a): t ) s i i traretinal cystoid macular edem and
subretinal fluid that almost completely resolved after I I i plant ((a): bottom). OCTA of superficial
plexus ((b): top) showing reduction of superficial vessel density and interruption of perifoveal
anastomotic arcades with partial increase of vessel density after edema disappearance at 60 days
after IDI implant ((b): bottom). OCTA of the deep plexus at baseline ((c): top) showing telangiectatic
and rarified vessels and no flow areas related to retinal cysts and hard exudates; after IDI implant
((c): top) it is evident a reduction of vessel caliber appearing less angiectatic, a vessel density increase
and partial cysts disappearance. OCTA of choriocapillaris ((d): top) at baseline showing focal areas
of no flow probably related to a masking effect due to retinal edema and hard exudate that partially
decrease after IDI ((d): bottom).
2.5. Correlation Analysis between Different Parameters
SCPD and DCPD relative variation from baseline to 120 days in the foveal and parafoveal area
did not show any significant correlation with foveal and parafoveal CMT relative variation (Table 3).
Table 3. Pearson’s Correlation coefficient among thickness, density, and functional parameters
expressed as relative variation from baseline to 120 days.
Variable CMT Fovea CMT Parafovea
SCPD
Whole −0.490 −0.121
Fovea −0.322 0.224
Parafovea −0.470 0.034
DCPD
Whole 0.187 0.616
Fovea −0.220 0.132
Parafovea 0.308 0.689
CCD
Whole 0.146 0.048
Fovea −0.724 ** −0.799 **
Parafovea 0.222 0.078
ODVD
Whole 0.243 −0.131
Inside 0.044 0.220
Peripapillary −0.543 −0.257
4◦ MP −0.028 0.251
BCVA 0.123 −0.365
* p < 0.05; ** p < 0.01 after FDR correction. FDR = fal e discover rate, CMT = Central Macular Thickness;
SCPD = Superficial capillary plexus density; DCPD = Deep capillary plexus density; CCD = Choriocapillaris density;
ODVD = Optic disc vessel density; MP = microperimetry; BCVA = best corrected visual acuity.
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A significant negative correlation was found between CCD relative variation and CMT relative
variation in foveal and parafoveal areas (respectively, r = −0.724; p < 0.01 and r = −0.799; p < 0.01).
3. Discussion
In this study, using OCTA, we investigated retinal superficial and deep vessel densities and
choriocapillaris density in patients with diabetic retinopathy complicated by macular edema at
baseline and after an intravitreal dexamethasone implant. Overall, we found a reduction of foveal
and parafoveal retinal superficial and deep vascular density, and choriocapillaris density compared
to normal controls. In addition, peripapillary vessel density was also decreased compared to
controls. Retinal superficial and deep vessel density did not change significantly after intravitreal
dexamethasone implant; on the contrary, choroid vessel density showed a tendency toward an increase.
The spread of OCTA allowed for a better assessment of the microvascular retinal alterations
in DR and DME patients. Some previous studies have reported retinal capillary network and
choriocapillaris abnormalities in patients with diabetic retinopathy, such as a decrease of vessel density,
with a significant decrease of capillary perfusion density values as retinopathy progresses [12–15].
The reduction of vessel density was more consistent in the deep capillary plexus and choriocapillaris
compared to the superficial plexus [12,15].
Similarly, in our study, the vessel density of both superficial and deep capillary plexuses of the
DME patients was lower than in the healthy controls with DCPD being much more affected than SCPD.
Superficial capillary plexus density was significantly reduced in the parafoveal area (p < 0.001),
while deep capillary plexus and choriocapillaris densities were significantly reduced both in the foveal
(p < 0.05) and parafoveal area (p < 0.001 and p < 0.01, respectively).
At qualitative analysis the superficial capillary plexus was rarified with interruption of the
perifoveal anastomotic arcade, and deep plexus was rarified with evidence of telangectatic vessels
particularly in areas of macular edema. In addition, peripapillary vessel density is significantly
decreased in DME eyes compared to controls (p < 0.05).
In reference [12], it has been speculated that integrity of the DCP could be a possible predictor
of the effectiveness of the treatment, probably related to its role in excess fluid removal from the
retina, thus preserving it from macular edema. In fact, Junyeop et al. found a significant correlation
between the status of the DCP and the treatment response. The DCP of poor responders showed
greater damage, such as a lower vascular flow density, a higher mean number of microaneurysms,
and a larger foveal avascular area in comparison with the good responders.
They did not find any association between flow density of the superficial retinal vessels and
retinal thickness before and after the treatment [12].
In the current study, no correlation was found between SCPD/DCPD and CMT at baseline.
After the IDI implant, the SCPD and DCPD in the foveal and parafoveal area did not modify
significantly during the entire follow up, although retinal macular thickness significantly decreased.
It has been demonstrated that intravitreal steroid, such as dexamethasone or triamcinolone in
eyes with macular edema due to retinal vein occlusion or diabetic retinopathy, causes a reduction of
arteriolar or venular vessel diameter probably due to a blockage of vascular endothelial growth factor
with macular edema improvement [16,17].
At a subjective evaluation, we observed a normalization of vessel caliber after retinal edema
resolution with deep vessels being less angiectatic; nevertheless, at a quantitative vessel density
analysis, we did not find a significant change of vessel density both in the superficial and deep plexuses.
This is probably due to the ischemic damage of retinal vessels that do not recover after treatment.
The CCD after treatment showed a weak tendency to an increase. We can hypothesize that
overlying pathologic retina due to edema could attenuate the OCT signal with choriocapillaris
appearing reduced.
As already reported by Spaide, en face imaging that relies on segmentation strategies is
problematic in diseased eyes due to image artifacts. In cases of retinal edema, retinal segmentation
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can be problematic due to an increase of layer thickness and contemporary decrease of contrast
between different layers causing automatic recognition of retinal layers and resulting segmentation
based on segmentation of healthy retina to fail. In addition, the increase in thickness of retinal layers
could reduce the signal strength of the underlying choroid, thus causing a misleading vessel density
analysis [18].
In the DME group, peripapillary vessel density was significantly reduced compared to that
of healthy subjects. Peripapillary vessels’ features in patients with diabetic retinopathy have been
previously investigated in the literature with other imaging techniques. Hamanaka et al. evaluated
retinal ischemia in the peripapillary area in patients with proliferative diabetic retinopathy using
fluorescein angiography, and correlated the extension of peripapillary capillary occlusion to angle
neovascularization [19]. Moradi et al. showed that wider baseline peripapillary retinal venular caliber
may be a predictor of better visual outcome in DME eyes treated with anti-VEGF, probably related to
intraocular level of VEGF [20].
Recently, Rao et al. investigated peripapillary vessel density in patients with systemic diseases
such as diabetes and systemic hypertension using OCTA. They observed a lower peripapillary vessel
density in diabetics than in healthy controls [21]. Our results confirm this finding; nevertheless,
we evaluated only patients with moderate DR complicated by DME, thus it is not possible to generalize
these results to all stages of DR with or without DME, and establish a relationship with DME.
Functional parameters such as visual acuity and microperimetry increased after IDI implant
related to macular thickness decrease.
A trend toward an improvement in visual acuity was observed after IDI with the highest gain at
60 days after the treatment. Retinal sensitivity detected with microperimetry significantly improved,
as soon as the 7-day control reached the lowest value at 60 days, and remained stable at 90 days with
an increase at 120 days after IDI, not reaching the preoperative values.
The effect peak of the dexamethasone implant has been previously reported to be at 30 days with
a mean duration of the treatment being at four months [22].
Shah et al. reported that also in vitrectomized eye implantation of the IDI appeared to be
efficacious in improving visual acuity and CMT with the observed benefits persisting for at least for
three months [23].
4. Materials and Methods
4.1. Study Participants
Twenty-five type 2 diabetic retinopathy patients with a moderate stage of DR (according to the
simplified version of the Early Treatment of Diabetic Retinopathy Study (ETDRS) classification aimed
by the American Academy of Ophthalmology Guidelines Committee) complicated by center-involved
DME and candidates to IDI were enrolled in this prospective study [24]. The diagnosis of DR was
made by means of fundus examination. In addition, fluorescein angiography (FA) and Spectral optical
coherence tomography (SD-OCT) were performed in all cases.
Criteria for inclusion were: (1) age >18 years old; (2) best-corrected visual acuity (BCVA) greater
than 0.5 logMAR in the study eye at baseline examination; (3) presence of treatment naïve recent
center-involved DME (less than 3 months); (4) central macular thickness (CMT) > 300 µm as measured
using SD-OCT at the baseline examination.
The exclusion criteria were: (1) any previous ocular surgery (included intravitreal injections) in
the last 6 months; (2) laser treatments; (3) history of glaucoma and other conditions to contraindicate
steroid treatment; (4) retinal vascular diseases; (5) medium lens opacities (according to the Lens
Opacities Classification System).
For each patient, the eye with lowest BCVA was selected, and in the case of equality of BCVA
between the two eyes, the patient was given the choice.
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Twenty-five age-matched healthy subjects were included as controls. The study adhered to
the tenets of the Declaration of Helsinki and was approved by the Ethical Committee “Department
of Medicine and Science of Aging, University “G. D’Annunzio” Chieti-Pescara, Italy” (LED, v01,
February 2016). Written informed consent was provided for all the patients enrolled in the study.
4.2. Study Protocol
All recruited patients underwent a complete ophthalmic evaluation, including assessment of
BCVA, tonometry, slit-lamp biomicroscopy, and indirect fundus ophthalmoscopy.
BCVA was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.
All patients were tested by means of XR Avanti® AngioVue OCTA (Optovue Inc., Fremont,
CA, USA).
FA images previously acquired with Heidelberg Retina Angiograph 2 HRA2 (HRA+OCT
Spectralis: Heidelberg Engineering, Heidelberg, Germany) were used to confirm the stage of the
diabetic retinopathy by two independent experienced retina specialists (LT and RDA).
All of the patients with no ocular or systemic contraindications to steroid treatment and signing
an informed consent were treated with a sustained-release dexamethasone 0.7 mg intravitreal implant
(IDI; Ozurdex®, Allergan, Inc., Irvine, CA, USA) within 7 days from baseline examination.
4.3. Procedures
4.3.1. SD-OCT Angiography with XR Avanti
XR Avanti® AngioVue OCTA (Optovue Inc., Fremont, CA, USA) is a device with a high-speed
of 70,000 axial scans per second, using a light source of 840 nm, and an axial resolution of 5 µm.
The AngioVue OCTA system, based on the SSADA algorithm (Version: 2015.1.0.90, Optovue, Inc.,
Fremont, CA, USA), uses blood flow as intrinsic contrast. Indeed, the flow is detected as a variation
over time in the speckle pattern formed by interference of light scattered from red blood cells (RBC)
and adjacent tissue structure [25,26].
Before imaging, each subject’s pupils were dilated with a combination of 0.5% tropicamide and
10% phenylephrine. Study participants underwent SD-OCT imaging following a protocol that included
AngioVue OCT 3D volume set of 3× 3 mm2, consisting of 304× 304 pixels in the transverse dimension.
An internal fixation light was used to center the scanning area.
One FastX (horizontal raster) set and one FastY (vertical raster) set were performed for each
acquisition scan. Scans with low quality (i.e., if the subject blinked or if there were significant motion
artifacts) were excluded and repeated until good quality was achieved. Three scans for each patient
were captured (all with a signal straight index >60) and the scan of best quality was chosen for analysis.
4.3.2. Vascular Layer Segmentation
Vascular retinal layers were visualized and segmented based on the default settings of the
automated software algorithm of the XR Avanti AngioVue OCTA [27]. The superficial plexus consists
of the capillaries 3 µm below the internal limiting membrane (ILM) to 15 µm below the inner plexiform
layer (IPL). The deep plexus extends from 15 µm to 70 µm below the IPL. The choriocapillaris consists
of capillaries in a 30 µm thick layer posterior to the retinal pigment epithelium-Bruch membrane
junction. The software option to remove projection artifacts from inner vascular plexus in the outer
retina was selected. Two observers (LT and RDA) independently checked image quality and excluded
poor quality images leading to possible segmentation errors.
4.3.3. Quantitative Vessel Analysis
Objective quantification vessel density was evaluated on the OCTA en face images for each eye
using the AngioVue software (Optovue, Inc., Fremont, CA, USA). The flow area was calculated with
a user defined circular region of interest (ROI) and a threshold. The area within the ROI with intensities
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greater than the threshold was calculated. The vessel density was defined as the percentage area
occupied by vessels in a circular ROI centered on the center of the foveal avascular zone and with
a diameter of 2.5 mm. The AngioVue software automatically splits the ROI into two fields: the foveal
area, a central circle with a diameter of 1 mm; and the parafoveal area that constitutes the remaining
part inside the ROI [27].
For each patient whole en face (foveal and parafoveal) vessel density, foveal vessel density,
parafoveal vessel density, parasuperior and parainferior vessel density in the superficial plexus, deep
plexus and in the choriocapillaris were measured.
4.3.4. Qualitative Vessel Analysis
Two independent observers (LT and RDA) subjectively evaluated OCTA in the 3 × 3 mm2 scan of
best quality. Vascular anomalies were evaluated in terms of vessels caliper (regular or irregular such as
telangectasic vascular abnormalities and/or microaneurysms), vessel coarse (regular or irregular such
as distorted) and density (normal or rarified).
Perifoveal capillaries were evaluated to disclose disruption or integrity of the perifoveal
anastomotic arcades.
Observers were masked about the status of treatment (baseline or post-treatment at different
follow up points) of the patient whose images they were analyzing.
4.3.5. Foveal and Parafoveal Retinal Thickness Analysis
Central macular thickness was automatically calculated by the software on the OCTA 3 × 3 mm2
volume scan (XR Avanti®; Optovue, Inc., Fremont, CA, USA) from ILM to retinal pigment epithelium
(RPE). A circular ROI centered on the center of the foveal avascular zone with a diameter of 2.5 mm
was considered for retinal thickness analysis: central foveal area (1 mm of diameter) and parafoveal
area that constitutes the remaining part inside the ROI (total parafoveal area or temporal, superior,
nasal, and inferior quadrants).
4.3.6. Microperimetry
Microperimetry was performed by means of the MP-1 Microperimeter (Nidek Technologies, Padova,
Italy), the latter using an infrared fundus camera with a liquid crystal display software-controlled.
All patients were dilated with tropicamide 1% eye drops and, after a pre-test training, 5 min of
dark adaptation were performed. The test is routinely carried out with an automated eye tracking
system, which provides real-time compensation for eye movements and allows improved presentation
of a stimulus at the predefined retinal location. During the test, the patient was encouraged to fix a red
ring target, 1◦ in diameter, on a white monochromatic background at 4 asb. Then, the retinal sensitivity
was tested by means of a customized radial grid centered on the fovea and having 77 Goldman III
stimuli covering the central 20◦. Therefore, the retinal sensitivity can be measured easily because
the level of stimulation changes automatically and progressively during the microperimetry test.
The stimulus intensity ranged from 0 dB to 20 dB (0 dB corresponded to the strongest signal intensity
of 127 cd/m2) in 1-dB steps, and the duration of each stimulus was 200 milliseconds. Finally, in order
to improve the correlation between microperimetric data with retinal characteristics, results were
matched with a color digital retinography obtained with the MP1 color fundus camera. To assess
central macular retinal sensitivity, differential light threshold values were compared by calculating the
mean of the central 4◦ of macular area which was averaged automatically by the MP-1 microperimetry
software program of mean sensitivity in a polygon.
4.3.7. Treatment
Sustained-release dexamethasone 0.7 mg intravitreal implant (Ozurdex®, Allergan, Inc., Irvine,
CA, USA) was injected in the vitreous cavity of all patients. All injections were performed in
an operation room, and IDI was inserted into the vitreous cavity through the pars plana using
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a customized, single-use 22-gauge applicator. Patients were treated with a topical ophthalmic antibiotic
for 10 days after the treatment.
4.3.8. Main Outcome Measures
Patients were examined at baseline, at 7 days, 30 days, 60 days, 90 days, and 120 days after the
IDI implantation.
Main outcome measures were mean VA; microperimetry at 4◦; foveal and parafoveal vessel
density, and central macular thickness.
4.3.9. Sample Size Determination and Statistical Analysis
The estimation of the number of eyes was based on the main endpoint criteria. A planned sample
size of 25 patients was expected to provide 80% power for a two-sided test with significance level
of 0.05, assuming an effect size of 17% indifference of BCVA after seven days of implantation with
between subjects’ pooled standard deviation of 0.3 logMAR.
The quantitative variables were summarized as mean and standard deviation (SD), qualitative
variables as frequency and percentage. A Shapiro–Wilk’s test was performed to evaluate the departures
from normality distribution for each variable.
Student’s t-test was performed to compare quantitative parameters between controls and
DME patients.
Repeated-measures ANOVA with linear trend analysis were performed to evaluate the effect of
time on each parameter. Contrast analysis was performed to evaluate differences of each parameters
from previous measurement.
The Pearson correlation coefficient (R) was performed to evaluate the correlation among BCVA,
microperimetry sensitivity, foveal thickness, and vessel density. The false discovery rate correction
(FDR) was used to control the family-wise type I error rate, and an FDR adjusted p-value less than
0.05 was determined to be statistically significant. Statistical analysis was performed using IBM® SPSS
Statistics v 20.0 software (SPSS Inc., Chicago, IL, USA).
5. Conclusions
In conclusion, our study demonstrated that retinal vessel density is reduced in DME eyes with
the main involvement of the deep plexus, and that vessel density does not recover after intravitreal
steroid treatment. At a morphologic qualitative analysis, deep vessels show a caliber normalization
appearing less angiectatic. Partial increase of choriocapillaris density after treatment should be better
explored to evaluate the reliability of this finding or attribute it to a limit of OCTA in choriocapillaris
analysis in eyes with pathologic overlying retina. Moreover, a longer follow up would be needed to
better investigate vascular remodeling in a condition free from macular edema recurrence.
Undoubtedly, OCT angiography represents a fundamental tool in investigating the fine blood
vessels in the macula and optic disc, allowing a better comprehension of DME pathogenesis.
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